Researchers found that hypoxia was associated with elevated genomic instability in 10 tumor types and saw widespread hypoxia-associated dysregulation of miRNAs.
The finding could help detect autologous blood doping among athletes, Dark Daily reports.
A 19-miRNA panel showed high sensitivity and specificity for differentiating benign and malignant thyroid nodules.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
The company said that given recent debt restructuring efforts and certain regulatory and payor approvals of its products, it's on track for a strong 2017.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The team recently received funding to develop and validate an assay to help guide clinical decision making when pancreatic cancer precursor lesions are detected.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.